Mei-Wei Lin

Manager
Industrial Technology Research Institute

​

Mei-Wei earned her Ph.D. in Biomedical Engineering from National Tsing Hua University in 2020, supported by a sponsorship from the Industrial Technology Research Institute (ITRI). During her doctoral studies under the guidance of Prof. Yu-Chen Hu, she specialized in synthetic biology and CRISPR technology. Her early research focused on engineering baculoviruses with miRNA-responsive switches for liver cancer therapy, which was published in Nucleic Acids Research (2018) and recognized at the ASGCT 20th Annual Meeting with a Meritorious Abstract Travel Award.
As gene and cell therapies gained momentum globally, Mei-Wei further pursued research on CRISPR/Cas13d-mediated transcriptome modulation in CHO cells to enhance antibody expression and quality. The results were published in JTICE (2021) and later received the Outstanding Paper Award from the Taiwan Institute of Chemical Engineers (TwIChE) in 2022.
At ITRI, Mei-Wei has accumulated over 15 years of experience, working across several domains including cellular modification, antibody optimization, and precision gene editing. She established patient-derived liver cancer stem cell models for drug testing and hepatitis C virus studies, and contributed to the development of an anti-TIGIT immune checkpoint antibody, which was honored with the National Innovation Award in 2022 and granted patents in both Taiwan and Japan. She also initiated an international collaboration with System Biosciences (USA) to apply CRISPR technology in genome editing.
Throughout her career, Mei-Wei has valued the opportunity to collaborate with talented colleagues and mentors across disciplines. She remains committed to continuous learning and advancing the translation of scientific insights into impactful biomedical applications.​

 

Speech title & Synopsis

Promega Bioassays: Enabling Reliable Methodology for Research and Industrial Advancement

Promega Bioassays: Enabling Reliable Methodology for Research and Industrial Advancement
The development of robust, reproducible bioassays is critical for the evaluation of therapeutic antibodies and the advancement of immunotherapy research. Leveraging bioassay platforms of Promega, we have successfully implemented various functional assay—including OX40L, IL-21, IL-12, and CD40L agonist bioassays, ADCC reporter assays, and immune checkpoint blockade assays—to accelerate antibody discovery and development. These bioassays provided reliable, mechanism-of-action (MoA)-reflective tools for characterizing antibody function and potency.
 
By integrating Promega’s reliable bioassay systems into collaborative R&D projects, we enhanced the efficiency of antibody screening workflows and achieved consistent evaluation across various stages of development. This approach highlights the critical role of high-performance cell-based bioassays in bridging basic research and industrial translation. Furthermore, implementing these bioassays has enabled more effective cooperation with academic institutions and and biotech companies.